Search

Displaying results 631 - 640 of 10000 in total
  1. Target

    Melanocortin receptor 4

    go.drugbank.com/bio_entities/BE0009682
    TargetHumans

    G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha- and beta-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor (PubMed:12646665, PubMed:14764818, PubMed

    Polypeptides: Melanocortin receptor 4Function: corticotropin receptor activity
  2. Target

    Prosaposin receptor GPR37

    go.drugbank.com/bio_entities/BE0011479
    TargetHumans

    Acts as a receptor for several ligands including prosaposin, osteocalcin or neuroprotectin D1. … Acts as a receptor for osteocalcin (OCN) to regulate oligodendrocyte differentiation and central nervous system myelination.

    Polypeptides: Prosaposin receptor GPR37Synonyms: Parkin-associated endothelin receptor-like receptor, G protein-coupled receptor 37
  3. Target

    Relaxin receptor 1

    go.drugbank.com/bio_entities/BE0019700
    TargetHumans

    Receptor for relaxins. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP.

    Polypeptides: Relaxin receptor 1Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 7, Relaxin family peptide receptor 1
  4. Target

    Urotensin-2 receptor

    go.drugbank.com/bio_entities/BE0020904
    TargetHumans

    G protein-coupled receptor for the vasoactive neuropeptides urotensin-2 and urotensin-2B (PubMed:14550283).

    Polypeptides: Urotensin-2 receptorSynonyms: Urotensin II receptor, G protein-coupled receptor 14
  5. Drug

    Minoxidil

    go.drugbank.com/drugs/DB00350
    ApprovedInvestigational

    A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

    Products: Re-Gro, ALOPEXY T %5 DERI SPREYI, 60 ML
  6. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    The majority of the prescriptions written were for injectable (66%) and topical (32%) testosterone products. As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.' … This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.

  7. Drug

    Furosemide

    go.drugbank.com/drugs/DB00695
    ApprovedInvestigationalVet approved

    Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. … [L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body.

    Products: KARSEMID 20 MG/2ML IM/IV ENJEKSIYON VE INFÜZYONLUK ÇÖZELTI, 5 ADET, TURKTIPSAN FUROSEMİD 20 MG/2 ML ENJEKSİYONLUK VE İNFÜZYONLUK ÇÖZELTİ, 5 ADET
  8. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. … Some of their side effects are also caused by actions in the CNS.

  9. Drug

    Selenious acid

    go.drugbank.com/drugs/DB11127
    Approved

    The reports from such studies have heightened the interest in additional human selenium supplementation studies to validate the results in larger populations [L1918]. … Selenium (Se) has been demonstrated to prevent cancer in numerous animal models when administered selenium at levels exceeding the nutritional requirements.

    Mixtures: Micro+ Te Pediatric, Vitamins C Plus E W.beta Carotene and SeProducts: Micro Se, Formula-SE
  10. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes. … [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018.